Hypothalamic vasopressin and oxytocin mRNA expression in relation to depressive state in Alzheimer's Disease: A difference with major depressive disorder

Journal of Neuroendocrinology

Volumn 21, Issue 8, 2009, Pages 722-729

  Meynen, G ^a   Unmehopa, U A ^a   Hofman, M A ^a   Swaab, D F ^a   Hoogendijk, W J G ^b  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Depression; Hypothalamic pituitary adrenal axis; Oxytocin; Post mortem brain tissue; Vasopressin

Indexed keywords

MESSENGER RNA; OXYTOCIN; VASOPRESSIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; IN SITU HYBRIDIZATION; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SUPRAOPTIC NUCLEUS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARGININE VASOPRESSIN; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYPOTHALAMUS; MALE; NEURONS; OXYTOCIN; PROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 67650708817     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2009.01890.x     Document Type: Article

References (65)

1. Lee HB, Lyketsos CG. Depression in Alzheimer's disease: Heterogeneity and related issues. Biol Psychiatry 2003; 54: 353-362.
2. Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004; 17: 55-64.
3. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry 2005; 162: 2086-2093.
4. Broe GA, Henderson AS, Creasey H, McCusker E, Korten AE, Jorm AF, Longley W, Anthony JC. A case-control study of Alzheimer's disease in Australia. Neurology 1990; 40: 1698-1707.
5. Saez-Fonseca JA, Lee L, Walker Z. Long-term outcome of depressive pseudodementia in the elderly. J Affect Disord 2007; 101: 123-129.
6. Sultzer DL. Neuroimaging and the origin of psychiatric symptoms in dementia. Int Psychogeriatr 1996; 8 (Suppl 3):239-243.
7. Berger AK, Fratiglioni L, Forsell Y, Winblad B, Backman L. The occurrence of depressive symptoms in the preclinical phase of AD: A population-based study. Neurology 1999; 53: 1998-2002.
8. Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: A community-based prospective study. Arch Gen Psychiatry 1999; 56: 261-266.
9. Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic. A three-year prospective study. Arch Neurol 1985; 42: 894-896.
10. Kral VA, Emery OB. Long-term follow-up of depressive pseudodementia of the aged. Can J Psychiatry 1989; 34: 445-446.
11. Devanand DP, Sano M, Tang MX, Taylor S, Gurland BJ, Wilder D, Stern Y, Mayeux R. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996; 53: 175-182.
12. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J, Pilat J, Beckett LA, Arnold SE, Evans DA, Bennett DA. Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 2002; 59: 364-370.
13. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression as a risk factor for Alzheimer disease: The MIRAGE study. Arch Neurol 2003; 60: 753-759.
14. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530-538.
15. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049-1051.
16. Thompson S, Herrmann N, Rapoport MJ, Lanctot KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: A metaanalysis. Can J Psychiatry 2007; 52: 248-255.
17. Appelhof BC, Huyser J, Verweij M, Brouwer JP, Van DR, Fliers E, Hoogendijk WJ, Tijssen JG, Wiersinga WM, Schene AH. Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol Psychiatry 2006; 59: 696-701.
18. Bao AM, Meynen G, Swaab DF. The stress system in depression and neurodegeneration: Focus on the human hypothalamus. Brain Res Rev 2008; 57: 531-553.
19. Antonijevic IA. Depressive disorders - is it time to endorse different pathophysiologies? Psychoneuroendocrinology 2006; 31: 1-15.
20. Hoogendijk WJ, Sommer IE, Pool CW, Kamphorst W, Hofman MA, Eikelenboom P, Swaab DF. Lack of association between depression and loss of neurons in the locus coeruleus in Alzheimer disease. Arch Gen Psychiatry 1999; 56: 45-51.
21. Hoogendijk WJ, Feenstra MG, Botterblom MH, Gilhuis J, Sommer IE, Kamphorst W, Eikelenboom P, Swaab DF. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol 1999; 45: 82-91.
22. Hoogendijk WJ, Meynen G, Endert E, Hofman MA, Swaab DF. Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression. Neurobiol Aging 2006; 27: 780-781.
23. Nemeroff CB, Vale WW. The neurobiology of depression: Inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66 (Suppl 7): 5-13.
24. Gerner RH, Wilkins JN. CSF cortisol in patients with depression, mania, or anorexia nervosa and in normal subjects. Am J Psychiatry 1983; 140: 92-94.
25. Meynen G, Unmehopa UA, Hofman MA, Swaab DF, Hoogendijk WJ. Relation between corticotropin-releasing hormone neuron number in the hypothalamic paraventricular nucleus and depressive state in Alzheimer's disease. Neuroendocrinology 2007; 85: 37-44.
26. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry 1988; 23: 271-284.
27. Swaab DF, Fliers E, Hoogendijk WJ, Veltman DJ, Zhou JN. Interaction of prefrontal cortical and hypothalamic systems in the pathogenesis of depression. Prog Brain Res 2000; 126: 369-396.
28. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993; 14: 76-122.
29. Swaab DF. The human hypothalamus. Basic and clinical Aspects. Part I: nuclei of the Hypothalamus. Handbook of Clinical Neurology. Amsterdam: Elsevier, 2003.
30. Engelmann M, Landgraf R, Wotjak CT. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 2004; 25: 132-149.
31. Wotjak CT, Kubota M, Kohl G, Landgraf R. Release of vasopressin from supraoptic neurons within the median eminence in vivo. A combined microdialysis and push-pull perfusion study in the rat. Brain Res 1996; 726: 237-241.
32. Gispen-de Wied CC, Westenberg HG, Koppeschaar HP, Thijssen JH, van Ree JM. Stimulation of the pituitary-adrenal axis with a low dose [Arg8]-vasopressin in depressed patients and healthy subjects. Eur Neuropsychopharmacol 1992; 2: 411-419.
33. Inder WJ, Donald RA, Prickett TC, Frampton CM, Sullivan PF, Mulder RT, Joyce PR. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry 1997; 42: 744-747.
34. Brunner J, Keck ME, Landgraf R, Uhr M, Namendorf C, Bronisch T. Vasopressin in CSF and plasma in depressed suicide attempters: preliminary results. Eur Neuropsychopharmacol 2002; 12: 489-494.
35. de Winter RF, van Hemert AM, DeRijk RH, Zwinderman KH, Frankhuijzen-Sierevogel AC, Wiegant VM, Goekoop JG. Anxious-retarded depression: Relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003; 28: 140-147.
36. Morimoto M, Morita N, Ozawa H, Yokoyama K, Kawata M. Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: An immunohistochemical and in situ hybridization study. Neurosci Res 1996; 26: 235-269.
37. Sanchez MM, Young LJ, Plotsky PM, Insel TR. Distribution of corticosteroid receptors in the rhesus brain: Relative absence of glucocorticoid receptors in the hippocampal formation. J Neurosci 2000; 20: 4657-4668.
38. Erkut ZA, Pool C, Swaab DF. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab 1998; 83: 2066-2073.
39. Purba JS, Hoogendijk WJ, Hofman MA, Swaab DF. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996; 53: 137-143.
40. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 1994; 60: 436-444.
41. Meynen G, Unmehopa UA, van Heerikhuize JJ, Hofman MA, Swaab DF, Hoogendijk WJ. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biol Psychiatry 2006; 60: 892-895.
42. van Londen L, Goekoop JG, van Kempen GM, Frankhuijzen-Sierevogel AC, Wiegant VM, van der Velde EA, De Wied D. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997; 17: 284-292.
43. van Londen L. Vasopressin in Major Depression. Leiden: Universitair Facilitair Bedrijf, Grafische Dienstverlening, 2003.
44. Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: The presence of multiple receptor imbalances. Mol Psychiatry 2008; 13: 786-799.
45. van West D, Del Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T, Sluijs S, Bel-Kacem S, Adolfsson R, Mendlewicz J, Van Duijn C, Deboutte D, Van Broeckhoven C, Claes S. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatry 2004; 9: 287-292.
46. Gimpl G, Fahrenholz F. The oxytocin receptor system: Structure, function, and regulation. Physiol Rev 2001; 81: 629-683.
47. Ludwig M. Dendritic release of vasopressin and oxytocin. J Neuroendocrinol 1998; 10: 881-895.
48. Leng G, Ludwig M. Neurotransmitters and peptides: Whispered secrets and public announcements. J Physiol 2008; 586: 5625-5632.
49. Legros J. Inhibitory effect of oxytocin on corticotrope function in humans: Are vasopressin and oxytocin ying-yang neurohormones? Psychoneuroendocrinology 2001; 26: 649-655.
50. Neumann ID, Wigger A, Torner L, Holsboer F, Landgraf R. Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: Partial action within the paraventricular nucleus. J Neuroendocrinol 2000; 12: 235-243.
51. Ochedalski T, Subburaju S, Wynn PC, Aguilera G. Interaction between oestrogen and oxytocin on hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol 2007; 19: 189-197.
52. Meynen G, Unmehopa UA, Hofman MA, Swaab DF, Hoogendijk WJG. Hypothalamic oxytocin mRNA expression and melancholic depression. Mol Psychiatry 2007; 12: 118-119.
53. Lucassen PJ, van Heerikhuize JJ, Guldenaar SE, Pool CW, Hofman MA, Swaab DF. Unchanged amounts of vasopressin mRNA in the supraoptic and paraventricular nucleus during aging and in Alzheimer's disease. J Neuroendocrinol 1997; 9: 297-305.
54. van de Nes JA, Kamphorst W, Ravid R, Swaab DF. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol 1998; 96: 129-138.
55. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
56. Harding AJ, Halliday GM, Ng JL, Harper CG, Kril JJ. Loss of vasopressin-immunoreactive neurons in alcoholics is dose- related and time-dependent. Neuroscience 1996; 72: 699-708.
57. Sivukhina EV, Dolzhikov AA, Morozov I, Jirikowski GF, Grinevich V. Effects of chronic alcoholic disease on magnocellular and parvocellular hypothalamic neurons in men. Horm Metab Res 2006; 38: 382-390.
58. Liu RY, Zhou JN, Hoogendijk WJ, van Heerikhuize J, Kamphorst W, Unmehopa UA, Hofman MA, Swaab DF. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J Neuropathol Exp Neurol 2000; 59: 314-322.
59. Guldenaar SE, Swaab DF. Estimation of oxytocin mRNA in the human paraventricular nucleus in AIDS by means of quantitative in situ hybridization. Brain Res 1995; 700: 107-114.
60. Shibahara S, Morimoto Y, Furutani Y, Notake M, Takahashi H, Shimizu S, Horikawa S, Numa S. Isolation and sequence analysis of the human corticotropin-releasing factor precursor gene. EMBO J 1983; 2: 775-779.
61. Lucassen PJ, Goudsmit E, Pool CW, Mengod G, Palacios JM, Raadsheer FC, Guldenaar SE, Swaab DF. In situ hybridization for vasopressin mRNA in the human supraoptic and paraventricular nucleus; quantitative aspects of formalin-fixed paraffin-embedded tissue sections as compared to cryostat sections. J Neurosci Methods 1995; 57: 221-230.
62. Wierda M, Goudsmit E, Van der Woude PF, Purba JS, Hofman MA, Bogte H, Swaab DF. Oxytocin cell number in the human paraventricular nucleus remains constant with aging and in Alzheimer's disease. Neurobiol Aging 1991; 12: 511-516.
63. Scott LV, Dinan TG. Vasopressin as a target for antidepressant development: An assessment of the available evidence. J Affect Disord 2002; 72: 113-124.
64. Vallotton MB, Merkelbach U, Gaillard RC. Studies of the factors modulating antidiuretic hormone excretion in man in response to the osmolar stimulus: Effects of oestrogen and angiotensin II. Acta Endocrinol (Copenh) 1983; 104: 295-302.
65. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 2001; 286: 2280-2288.